ARGOBIO
ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice , researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR . The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of disease applications. The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases. In contrast to other small molecule approaches, this results in an efficient and sustained degradation of target receptors, potentially resulting in superior efficacy in the clinic than modalities currently being employed by other emerging protein degradation technologies.
Initially driven by Madelon Maurice, who will join as the Principal Investigator, Laigo Bio is gearing up for preclinical lead development in the coming months, generating proprietary biologics for a selection of targets to showcase its potential. Laigo Bio receives strong support from seasoned entrepreneurs Neill Moray Mackenzie at ArgoBio and Emil Pot at Oncode, who will prepare the company for a Series A investment round as it aims to initiate its first clinical studies in 2025. Dr. Neill Moray Mackenzie at ArgoBio is a veteran of the IO field and Mr Emil Pot is an IP & business development expert at Oncode with 25 years of experience in life sciences.
Chris De Jonghe, Valorization Director of Oncode Institute, said: “SureTACsR is building on the innovative ideas that Dr. Maurice has initially validated with the support of Oncode’s Technology Development Fund. With the foundation of Laigo Bio, another exciting step forward is made towards the translation of Dr. Maurice’s innovations into effective, and tailored therapies for cancer patients. We are thrilled to join forces with ArgoBio in this initial seed round and consider it as a token of great confidence in the potential of this platform technology.”
Madelon Maurice of the UMC Utrecht, said: “We are extremely happy that ArgoBio is supporting my long-standing research here at the UMC Utrecht on how to interfere with signalling alterations that drive oncogenesis and bringing a team of experienced scientists and entrepreneurs to help with its translation to the clinic.”
Dr. Neill Moray Mackenzie of ArgoBio, said: “This is exactly why we put ArgoBio together last year – to fund these early-stage opportunities. I am especially pleased that Madelon Maurice, a renowned KOL in the field, is leading this novel approach to protein degradation which has great potential to open up a completely new biology in the field of cancer therapy.”
Shobhit Dhawan of Oncode Bridge Fund, said: “Targeted protein degradation is an exciting space and has gained validation in clinical studies with many players now entering the field. One key differentiator here is sustained degradation of cell membrane bound proteins with a biologic, which is a very novel approach, and we believe holds a lot of promise in oncology and many neurological indications. We look forward to supporting Madelon, Neill and Emil in their journey at Laigo Bio.”
***
About Argobio: www.argobiostudio.com
Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology, and immunology. Argobio selects and incubates these projects with the goal to create biotech companies and develop them up to a significant Series A financing. Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs.
Follow us on LinkedIn .
About Oncode Institute : https://www.oncode.nl/
Oncode Institute unites more than 900 excellent fundamental cancer researchers in the Netherlands. Our mission is to stimulate innovations in the diagnosis and treatment of cancer. The ultimate goal is to help patients survive, improve the quality of life for those affected and contribute to a more affordable healthcare system. Oncode Institute translates fundamental insights into the biology of cancer into new diagnostics, new drugs and innovative treatments. Oncode’s three strategic pillars to improve patient outcomes are Excellent Science, Collaboration and Valorization. Oncode is funded by The Dutch Cancer Society, together with the Ministries of Economic Affairs & Climate, Education Culture & Science and Health, Welfare & Sport, and Health~Holland, with a total amount of €120 million until 2022.
About Oncode Bridge Fund:
The Oncode Oncology Bridge Fund provides early-stage financing to help the creation and growth of new enterprises based on the science of Oncode Investigators. The Bridge Fund aims to accelerate the translation of innovative cancer research of the Oncode labs into treatment options, diagnostic methods and research tools that benefit patients and society as a whole.
About UMC Utrecht: https://www.umcutrecht.nl/en
UMC Utrecht is one of the top-ranked academic medical centers in Europe with the core tasks of care, research and education. With more than 12,000 employees, UMC Utrecht, of which the Wilhelmina Children's Hospital is a part, is one of the largest public healthcare institutions in the Netherlands and the largest employer in the Utrecht region. Our mission: together we improve the health of people and create the care of tomorrow. Together we create more value, because we believe that every person counts.
About Laigo Bio:
Laigo Bio is based on the research from the laboratory of Professor Madelon Maurice, known internationally for her contributions to the understanding of Wnt signaling, a key pathway for stem cell maintenance and tissue renewal. A main focus of her work is to uncover the mode-of-action of membrane-bound E3 ligases that control Wnt receptor turnover and are frequently mutated in cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005651/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi and Ant International Pilot AI-Enabled Forecasting Solution to Enhance FX Risk Management for Airline Customers18.7.2025 04:30:00 CEST | Press release
Ant International’s Falcon TST Model will give Citi’s clients an improved FX risk management solution when selling through e-commerce channels.Pilot airline customer of the jointly-developed solution has already seen a cost reduction in their Fixed FX Rates hedging programme for online ticket sales. Citi and Ant International announced today that they are piloting the use of Ant International's Falcon Time-Series Transformer (TST) Model to deliver an enhanced FX risk management solution for their customers. Developed with aviation clients as an initial use case, the solution aims to offer greater payment solutions for the airline industry, which processes billions of payment transactions annually. With airline travel set to continue growing, the joint solution combines Ant International's experience with airline payments and Citi's robust FX solutions to help the bank's clients manage their FX costs more efficiently. Ant International’s Falcon TST Model is a transformer architecture-ba
AGC Launches Innovative Fluoroelastomer Without the Use of Surfactants or Fluorinated Polymerization Solvents18.7.2025 04:00:00 CEST | Press release
AGC (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai)(TOKYO:5201), a world-leading manufacturer of glass, chemicals and other high-tech materials, proudly announces the launch of surfactant and fluorinated polymerization solvent free grades in its fluoroelastomer “AFLAS™ FFKM” series; the SF grades (the “Products”). The newly developed Products are manufactured entirely without the use of any surfactants*1 or fluorinated polymerization solvents*2. The Products offer high performance equivalent to that of conventional products, while meeting the growing market demand for fluoroelastomers that do not use surfactants or fluorinated polymerization solvents during the manufacturing process. This has been achieved through AGC’s innovative, proprietary polymer manufacturing technology (Surfactant-Free & Fluoro Solvent-Free Technology, hereafter the “Technology”). Initially, this Technology will be applied to the high-temperature-resistant type of FFKM fluoroelastomers and new grades
Andersen Consulting udvider platformen med tilføjelsen af HTP Group17.7.2025 18:46:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter med at udvide sin konsulentkapacitet med tilføjelsen af samarbejdsfirmaet Hoffman Talent Partners (HTP Group), et executive search- og konsulentfirma med hovedkvarter i Bruxelles, Belgien. HTP Group hjælper med at frembringe indflydelsesrige ledere til morgendagens organisationer. HTP formidler arbejdskraft ved hjælp af executive search, midlertidige stillinger og as-a-service-modeller sideløbende med ledelses- og it-konsulenttjenester. HTP Group opererer gennem tre enheder: Hightech Partners, som specialiserer sig i executive search og ledelsesrådgivning til virksomheder, der er aktive inden for digital transformation, Hoffman & Associates, som fokuserer på executive search og interim management på tværs af sektorer og funktioner på bestyrelses- og direktionsniveau, og Ataya & Partners, som fokuserer på digital governance og yder rådgivning inden for cybersikkerhed og databeskyttelse. "Organisationer under forandring har brug for ledelse, der kan holde t
Dubai Launches World’s First Icon Classification for Human–Machine Collaboration in Research and Publications17.7.2025 18:40:00 CEST | Press release
Classification system sets new standard for transparency in the age of AI-assisted knowledge creation Dubai has launched the world’s first icon-based classification system to represent the level of human–machine collaboration in the process of producing research, publications, and public-facing content. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717193317/en/ Dubai launches world’s first icon classification for Human–Machine Collaboration in research and publications (Infographic: AETOSWire) Developed by the Dubai Future Foundation (DFF), the Human–Machine Collaboration (HMC) Icons offer a new global standard for transparency, clearly indicating the extent to which humans and AI worked together throughout the creation process. The classification is free to use, copyrighted for consistency, and openly available for researchers, publishers, and content creators worldwide. His Highness Sheikh Hamdan bin Mohammed bin Rash
Battery Ventures Promotes Justin Rosner to Partner17.7.2025 15:47:00 CEST | Press release
Battery elevates 11 team members worldwide to bolster its multi-stage investment strategy across software/AI, infrastructure tech and industrial technology Battery Ventures, a global, technology-focused investment firm, today announced nearly a dozen new internal promotions across four offices, including the elevation of Justin Rosner—a specialist in industrial technology and life-science tools—to partner. Battery also named four new principals across its venture-capital and private-equity practices, highlighting the firm’s penchant for promoting talent from within the firm. The new principals are Sudheendra Chilappagari in San Francisco; Michael Hoeksema in New York; Lior Mallul in Tel Aviv; and Lauren Wedell in Boston. Wedell and Mallul both joined Battery in 2018, while Hoeksema joined in 2017. Chilappagari, a former founder and technology product executive, joined the firm in 2021. “These promotions highlight Battery’s continued, global investment focus, even in the face of macroec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom